# EDGAR Filing Document

**Accession Number:** 0000926326
**File Stem:** 0001104659-25-119083
**Filing Date:** 2025-12
**Character Count:** 15287
**Document Hash:** 3c7feaf2b960bc994ca50f06e1d6faae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-119083.hdr.sgml**: 20251208

**ACCESSION NUMBER**: 0001104659-25-119083

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251208

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251208

**DATE AS OF CHANGE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OMNICELL, INC.
- **CENTRAL INDEX KEY:** 0000926326
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTRONIC COMPUTERS [3571]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 943166458
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-33043
- **FILM NUMBER:** 251554719

**BUSINESS ADDRESS:**
- **STREET 1:** 4220 NORTH FREEWAY
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76137
- **BUSINESS PHONE:** 8774159990

**MAIL ADDRESS:**
- **STREET 1:** 4220 NORTH FREEWAY
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76137

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OMNICELL, Inc
- **DATE OF NAME CHANGE:** 20070412

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OMNICELL INC /CA/
- **DATE OF NAME CHANGE:** 20010625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OMNICELL COM /CA/
- **DATE OF NAME CHANGE:** 20000419

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): December 8, 2025

**OMNICELL, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-33043** | **94-3166458** |
| (State or other jurisdiction of <br>incorporation) | (Commission File Number) | (IRS Employer Identification Number) |

---

**4220 North Freeway**

**Fort Worth, TX 76137**

(Address of principal executive offices, including zip code)

**(877) 415-9990**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | OMCL | NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 7.01 Regulation FD Disclosure.**

On December 8, 2025, Omnicell, Inc. (the "Company") issued a press release announcing the launch of Omnicell Titan XT, its next generation, automated dispensing system designed to empower autonomous medication management. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description of Document** |
| [99.1](tm2532894d1_ex99-1.htm) | [Press release entitled "Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management" dated December 8, 2025](tm2532894d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | |
|:---|:---|
|  | OMNICELL, INC. |
| Date: December 8, 2025 | /s/ H. Baird Radford, III |
|  | H. Baird Radford, III |
|  | Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2532894d1_ex99-1img01.jpg)

Contact:

Betsy Martinelli

Director, Corporate Marketing

<u>betsy.martinelli@omnicell.com</u>

**Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management**

 

**Fort Worth, Texas – December 8, 2025** – Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, today announced the launch of Omnicell Titan XT, a transformational, enterprise version of automated dispensing systems (ADS). Designed to unify proven automation and powerful intelligence, Titan XT will deliver an enhanced and more efficient medication management experience to support a growing health system.

"The introduction of Titan XT marks a significant milestone for Omnicell and the journey to cloud-enabled, autonomous medication management," said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. "Starting with nursing floors, we are now focused on integrating every care area into the OmniSphere platform to build what we believe will be the most complete, connected automation ecosystem in healthcare."

For pharmacy leaders, guided pharmacy task management, delivered through ongoing OmniSphere releases, is expected to provide enterprise-wide visibility and greater control of medication inventory management, through:

&nbsp;&nbsp;&nbsp;&nbsp;· DynamicRestock – action-oriented, guided workflows to simplify pharmacy
technician tasks and give pharmacy staff more time for higher-value activities;

&nbsp;&nbsp;&nbsp;&nbsp;· Centralized control of inventory management that standardizes configurations, med assignment, and recall management across the enterprise;
and

&nbsp;&nbsp;&nbsp;&nbsp;· AI-enabled intelligence capabilities to synthesize internal and external
medication inventory data that will help to predict stock risks early, empower proactive decisions, and drive systemwide optimization.

"The ability to assign new drugs to be added through OmniSphere has significantly improved cabinet restocking," said Terry Spurlin, clinical informatics pharmacist at Holzer Regional Medical Center. "My pharmacy technicians know exactly where to place those drugs when they go to stock the cabinet, resulting in about a 70 percent time savings for that workflow."

For nurses, a simple dispensing experience helps to minimize time spent on locating medications. "Nursing time is everything. The less time nurses spend at the cabinet means more time at the bedside which is critical for patient care," according to one pharmacy leader who consulted on the design of Titan XT.

Titan XT fosters safer medication administration for nursing teams through FiveRights, embedded safeguards designed to mitigate common error sources and reduce workflow disruptions, including:

&nbsp;&nbsp;&nbsp;&nbsp;· Look alike, sound alike (LASA) and override management alerts to support
dispensing safety and the industry-defined five rights of medication administration;

&nbsp;&nbsp;&nbsp;&nbsp;· Targeted alerts designed to reduce alarm fatigue; and

&nbsp;&nbsp;&nbsp;&nbsp;· Simplified medication retrieval workflows designed to expedite staff onboarding
and reduce training burden.

OmniSphere is designed to break down silos across the medication use journey. Starting at nursing floors with the launch of Titan XT, Omnicell's innovation roadmap envisions adding new care areas over time, delivering a connected medication management ecosystem designed to improve efficiency and enhance patient safety.

Titan XT is now available for purchase in the United States and anticipated for international purchase later in 2026, with ongoing OmniSphere releases beginning in early 2027.

**About Omnicell** 

Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

**Forward-Looking Statements**

To the extent any statements contained in this press release deal with information that is not historical, these statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," "target," "estimate," "seek," "predict," "project," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell's control. Such statements include, but are not limited to, Omnicell's expectations regarding our planned new products, solutions, services, technologies and innovations and developing new or enhancing existing products, solutions, services, technologies and innovations, including Omnicell Titan XT and OmniSphere and the related objectives and expected benefits (and any implied financial impact), integrating care areas into OmniSphere, continuing to add new care areas to Omnicell's innovation roadmap, delivering a connected medication management ecosystem, the ability to purchase, and expected availability to ship, Omnicell Titan XT, and statements about Omnicell's strategy, plans, objectives, promise and purpose, goals, opportunities, and market or Company outlook. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell's ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) delays in installations of our medication management solutions or our more complex medication packaging systems, (v) risks related to Omnicell's investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis (vi) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (vii) Omnicell's ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (viii) risks related to the incorporation of artificial intelligence technologies into our products, services and processes or our vendors offerings, (ix) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (x) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same, (xi) any disruption in Omnicell's information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xii) Omnicell's ability to recruit and retain skilled and motivated personnel, (xiii) Omnicell's ability to protect its intellectual property, (xiv) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xv) Omnicell's dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xvi) other risks and uncertainties further described in the "Risk Factors" section of Omnicell's most recent Annual Report on Form 10-K, as well as in Omnicell's other reports filed with or furnished to the United States Securities and Exchange Commission ("SEC"), available at <u>www.sec.gov</u>. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

OMCL-E